For informational and research purposes only.
Research, explained. Explore peptides, supplements, hormone health, longevity and red light therapy with clear, practical breakdowns of what the studies actually tell us.
Metabolism, recovery and emerging research
China's mazdutide approval concerns a defined product and use. Local access, product identity, importation and athlete eligibility require separate checks.
Read articleThe headline weight-loss result came from a specific population. Age, diabetes status, eligibility and the analysis all affect its relevance.
Read articleStopping zenagamtide, withdrawing from a study and reporting an adverse event are different outcomes. The trial protocols explain why that matters.
Read articleForzinity's approval applies to a defined prescription product and indication. Learn why an SS-31 name or purity claim cannot establish equivalence.
Read articleThe larger EGF–GHRP-6 stroke trial missed its main endpoint. Understand the early pilot, subgroup findings, safety and limits for recovery after stroke.
Read articlePulsatile gonadorelin depends on a complete delivery and monitoring program. A listed drug or historical approval does not establish access to the required pump.
Read articleTrust-game findings, a recent preregistered study and social-comparison experiments explain why context matters in oxytocin research.
Read articleRECLAIM reported fewer heavy-drinking days with pemvidutide. Understand the phase 2 findings, their safety context and what still needs confirmation.
Read articleDog studies show why a response to desmopressin must be interpreted alongside the cause of thirst, urine findings, blood sodium and follow-up.
Read articleA pituitary response to gonadorelin does not establish fertility protection during testosterone therapy. Here is what the human evidence does and does not show.
Read articleUse the Huberman–Bakri peptide interview as a starting point for checking BPC-157 claims against rat experiments, small human reports and current regulatory evidence.
Read articleWithdrawal studies show that tesamorelin’s visceral-fat reduction is not reliably permanent. Durability and a follow-up plan belong in the first conversation.
Read article49–60 of 323 articles
